Molecular Oncology
Volume 4, Issue 3 , Pages 209-229 , June 2010

Triple-negative breast cancer: Present challenges and new perspectives

  • Franca Podo

      Affiliations

    • Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 06 49902686.
    • ,
  • Lutgarde M.C. Buydens

      Affiliations

    • Institute of Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
    • ,
  • Hadassa Degani

      Affiliations

    • Department of Biological Regulation, Weizmann Institute of Science, 76100 Rehovot, Israel
    • ,
  • Riet Hilhorst

      Affiliations

    • PamGene International BV, Nieuwstraat 30, 5211NL's-Hertogenbosch, The Netherlands
    • ,
  • Edda Klipp

      Affiliations

    • Theoretical Biophysics, Humboldt-Universität zu Berlin, Invalidenstr. 42, 10115 Berlin, Germany
    • ,
  • Ingrid S. Gribbestad

      Affiliations

    • Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), MTFS, 7489 Trondheim, Norway
    • ,
  • Sabine Van Huffel

      Affiliations

    • Department of Electrical Engineering (ESAT), Katholieke Universiteit Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium
    • ,
  • Hanneke W.M. van Laarhoven

      Affiliations

    • Department of Medical Oncology 452, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Jan Luts

      Affiliations

    • Department of Electrical Engineering (ESAT), Katholieke Universiteit Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium
    • ,
  • Daniel Monleon

      Affiliations

    • Fundacion Investigacion Hospital Clinico de Valencia/INCLIVA, Avda. Blasco Ibañez, 17, 46010 Valencia, Spain
    • ,
  • Geert J. Postma

      Affiliations

    • Institute of Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
    • ,
  • Nicole Schneiderhan-Marra

      Affiliations

    • Biochemistry, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Markwiesenstrasse 55, 72770 Reutlingen, Germany
    • ,
  • Filippo Santoro

      Affiliations

    • Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
    • ,
  • Hans Wouters

      Affiliations

    • Institute of Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
    • ,
  • Hege G. Russnes

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, N-0310 Oslo, Norway
    • Department of Pathology, Oslo University Hospital Radiumhospitalet, Montebello, N-0310 Oslo, Norway
    • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, N-0310 Oslo, Norway
    • Biomedical Research Group, Department of Informatics, University of Oslo, PO Box 1080 Blindern, N-0316 Oslo, Norway
    • ,
  • Elda Tagliabue

      Affiliations

    • Department of Experimental Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
    • ,
  • Anne-Lise Børresen-Dale

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, N-0310 Oslo, Norway
    • ,
  • for the FEMME Consortium

Received 19 January 2010 ,Accepted 16 April 2010.

References 

  1. Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299:1574–1587
  2. Aebersold R, Auffray C, Baney E, Barillot E, Brazma A, Brett C, et al. Report on EU-USA workshop: how systems biology can advance cancer research (27 October 2008). Mol. Oncol. 2009;3:9–17
  3. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer. 2005;12(Suppl. 1):S135–S144
  4. Alfieri R, Barberis M, Chiaradonna F, Gaglio D, Milanesi L, Vanoni M, et al. Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation. BMC Bioinformatics. 2009;10(Suppl. 12):S16
  5. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP. c-myc amplifications in primary breast carcinomas and their local recurrences. J. Clin. Pathol. 2006;59:424–428
  6. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod. Pathol. 2005;18:1623–1631
  7. Baselga J, Segalla JGM, Roché H, del Giglio A, Ciruelos EM, Cabral Filho S, et al. SOLTI-0701: a double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with locally advanced breast cancer. Eur. J. Cancer. 2009;Supplements 7, 3
  8. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 2009;27:526–534
  9. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000
  10. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 2007;104:181–189
  11. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–1728
  12. Belkic K. Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing. Isr. Med. Assoc. J. 2004;6:610–618
  13. Belluco C, Petricoin EF, Mammano E, Facchiano F, Ross-Rucker S, Nitti D, et al. Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann. Surg. Oncol. 2007;14:2470–2476
  14. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006;45:1033–1040
  15. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006;66:4636–4644
  16. Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res. 2009;11:R55
  17. Bishop CM. Neural Networks and Pattern Recognition. Oxford, UK: Oxford University Press; 1995;
  18. Bluthgen N, Legewie S, Kielbasa SM, Schramme A, Tchernitsa O, Keil J, et al. A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts. FEBS J. 2009;276:1024–1035
  19. Bogner W, Gruber S, Pinker K, Grabner G, Stadlbauer A, Weber M, et al. Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis?. Radiology. 2009;253:341–351
  20. Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res. Treat. 2007;101:233–245
  21. Borisov N, Aksamitiene E, Kiyatkin A, Legewie S, Berkhout J, Maiwald T, et al. Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. Mol. Syst. Biol. 2009;5:256
  22. Bosch A, Eroles P, Zaragoza R, Viňa JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev. 2010 Jan 7;(Epub ahead of print)
  23. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer–current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2009;153:13–17
  24. Bradley A, Medina D. Introduction: BRCA1 and BRCA2 in mammary gland development and tumorigenesis. J. Mammary. Gland Biol. Neoplasia. 1998;3:363–364
  25. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505–1510
  26. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Bruggenwirth HT, Tilanus-Linthorst MM, Bartels CC, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann. Oncol. 2006;17:391–400
  27. Brown SA, Kunz D, Dumas A, Westermark PO, Vanselow K, Tilmann-Wahnschaffe A, et al. Molecular insights into human daily behavior. Proc. Natl. Acad. Sci. U. S. A. 2008;105:1602–1607
  28. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008;105:9053–9058
  29. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008;26:1810–1816
  30. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 2009;115:359–363
  31. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502
  32. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007;13:2329–2334
  33. Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrows E, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol. 2008;26(Suppl. 15S):abstr 1009
  34. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34
  35. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE. 2009;4:e6693
  36. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U. S. A. 2005;102:3738–3743
  37. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008;14:1368–1376
  38. Chen KC, Csikasz-Nagy A, Gyorffy B, Val J, Novak B, Tyson JJ. Kinetic analysis of a molecular model of the budding yeast cell cycle. Mol. Biol. Cell. 2000;11:369–391
  39. Chen KC, Calzone L, Csikasz-Nagy A, Cross FR, Novak B, Tyson JJ. Integrative analysis of cell cycle control in budding yeast. Mol. Biol. Cell. 2004;15:3841–3862
  40. Chen JH, Agrawal G, Feig B, Baek HM, Carpenter PM, Mehta RS, et al. Triple-negative breast cancer: MRI features in 29 patients. Ann. Oncol. 2007;18:2042–2043
  41. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, et al. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol. Syst. Biol. 2009;5:239
  42. Chen X, Wang L. Integrating biological knowledge with gene expression profiles for survival prediction of cancer. J. Comput. Biol. 2009;16:265–278
  43. Chickarmane V, Peterson C. A computational model for understanding stem cell, trophectoderm and endoderm lineage determination. PLoS ONE. 2008;3:e3478
  44. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529–541
  45. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007;8:R215
  46. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol. Syst. Biol. 2007;3:140
  47. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 2007;25:2840–2846
  48. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–244
  49. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev. 2005;14:1108–1112
  50. Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann. Oncol. 2009;20:862–867
  51. Cornelis RS, Vasen HF, Meijers-Heijboer H, Ford D, van Vliet M, van Tilborg AA, et al Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum. Genet. 1995;95:539–544
  52. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, et al. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet. Cytogenet. 2006;165:151–156
  53. Dalgin GS, Alexe G, Scanfeld D, Tamayo P, Mesirov JP, Ganesan S, et al. Portraits of breast cancer progression. BMC Bioinformatics. 2007;8:291
  54. Davidson EH, McClay DR, Hood L. Regulatory gene networks and the properties of the developmental process. Proc. Natl. Acad. Sci. U. S. A. 2003;100:1475–1480
  55. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer. 2009;45(Suppl. 1):27–40
  56. de Vries EF, Rots MG, Hospers GA. Nuclear imaging of hormonal receptor status in breast cancer: a tool for guiding endocrine treatment and drug development. Curr. Cancer Drug Targets. 2007;7:510–519
  57. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007;13:4429–4434
  58. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 2008;14:8019–8026
  59. Duda R, Hart P, Stork D. Pattern Classification. New York, USA: Wiley; 2001;
  60. Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res. Treat. 2003;77:199–204
  61. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1995;56:265–271
  62. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56:471–474
  63. Ergűn A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ. A network biology approach to prostate cancer. Mol. Syst. Biol. 2007;3:82
  64. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921
  65. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2006;2:458–466
  66. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009;361:123–134
  67. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692–695
  68. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J. Med. Genet. 2004;41:1–5
  69. Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer. 2003;98:1569–1577
  70. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003;95:1482–1485
  71. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 2006;6:96
  72. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22–34
  73. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2005;102:9176–9181
  74. Garcia-Gomez JM, Luts J, Julia-Sape M, Krooshof P, Tortajada S, Robledo JV, et al. Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. MAGMA. 2009;22:5–18
  75. Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer: a review. Breast Cancer Res. Treat. 2009;116:17–29
  76. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat. Cell. Biol. 2009;11:1287–1296
  77. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, et al. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res. 2010;9:972–979
  78. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc. Natl. Acad. Sci. U. S. A. 2007;104:8685–8690
  79. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009;20:1319–1329
  80. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, et al. BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res. Treat. 2009;(Epub ahead of print)
  81. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002;62:1481–1488
  82. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305–318
  83. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 2006;24:5652–5657
  84. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1689
  85. Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: a phenotypically distinct entity. Arch. Pathol. Lab. Med. 2010;134:130–133
  86. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, et al. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis. Markers. 2003;19:69–94
  87. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J. Interferon Cytokine Res. 2005;25:297–310
  88. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res. Treat. 1998;52:261–288
  89. Henneges C, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, et al. Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer. 2009;9:104
  90. Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene. 2006;25:5837–5845
  91. Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascon A, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod. Pathol. 2007;20:1298–1306
  92. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr. Pharm. Des. 2008;14:3020–3032
  93. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96
  94. Hurvitz SA, Finn RS. What’s positive about ‘triple-negative’ breast cancer?. Future Oncol. 2009;5:1015–1025
  95. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 2005;5:341–354
  96. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal. 2009;2:ra62
  97. Irvin WJ, Carey LA. What is triple-negative breast cancer?. Eur. J. Cancer. 2008;44:2799–2805
  98. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078
  99. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet. 1995;345:1503
  100. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J. Pathol. 2005;207:260–268
  101. Japaze H, Emina J, Diaz C, Schwam RJ, Gercovich N, Demonty G, et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity?. Breast. 2005;14:3–10
  102. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 2009;284:122–130
  103. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer. 1997;33:362–371
  104. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15:454–460
  105. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. Breast Cancer. 2009;9:29–33
  106. Kholodenko BN. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. Eur. J. Biochem. 2000;267:1583–1588
  107. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005;23:7483–7490
  108. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65
  109. Kubista M, Rosner M, Kubista E, Bernaschek G, Hengstschlager M. Brca1 regulates in vitro differentiation of mammary epithelial cells. Oncogene. 2002;21:4747–4756
  110. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11:R31
  111. Lacroix M, Leclercq G. The “portrait” of hereditary breast cancer. Breast Cancer Res. Treat. 2005;89:297–304
  112. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998;90:1138–1145
  113. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 2002;20:2310–2318
  114. Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007;9:R30
  115. Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 2003;1:E10
  116. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006;172:973–981
  117. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2007;47:593–628
  118. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008;26:1275–1281
  119. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl. Acad. Sci. U. S. A. 2008;105:1680–1685
  120. Liu Y, Kulesz-Martin M. p53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis. 2001;22:851–860
  121. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006;19:264–271
  122. Lluch-Ariet M, Estanyol F, Mier M, Delgado C, Gonzalez-Velez H, Dalmas T, et al. On the implementation of HealthAgents: agent-based brain tumour diagnosis. In:  Annicchiarico R,  Cortes U,  Urdiales C editor. Agent-technology and E-health. Basel, Switzerland: Birkhäuser; 2008;p. 5–24
  123. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res. Treat. 2009;113:357–370
  124. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77:697–709
  125. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev. Med. Chem. 2009;9:1084–1101
  126. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115
  127. Melchor L, Benitez J. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. Carcinogenesis. 2008;29:1475–1482
  128. Mersin H, Yildirim E, Berberoglu U, Gulben K. The prognostic importance of triple negative breast carcinoma. Breast. 2008;17:341–346
  129. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  130. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int. J. Cancer. 2002;101:555–559
  131. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, et al. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int. J. Cancer. 2007;121:1017–1020
  132. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and end Results database. Cancer. 2007;110:876–884
  133. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer. 2009;9:631–643
  134. Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics. 2009;25:3151–3157
  135. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer. 2004;4:665–676
  136. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 2007;1:160–171
  137. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010;20:68–80
  138. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–527
  139. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004;10:5367–5374
  140. O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J. Clin. Oncol. 2009;(Suppl. 15S):abstr 3
  141. Orlando L, Renne G, Rocca A, Curigliano G, Colleoni M, Severi G, et al. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann. Oncol. 2005;16:1094–1099
  142. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998;51:227–238
  143. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 2003;9:3606–3614
  144. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009;27:1160–1167
  145. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 1999;96:9212–9217
  146. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  147. Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Fausto A, et al. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecularbases for non invasive ima ging approaches. Curr. Med. Imaging Rev. 2007;3:123–137
  148. Polyak K. Breast cancer: origins and evolution. J. Clin. Invest. 2007;117:3155–3163
  149. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat. Genet. 2007;39:1338–1349
  150. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006;208:495–506
  151. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32
  152. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008;26:2568–2581
  153. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 2009;15:2302–2310
  154. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108–118
  155. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:R8–R17
  156. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 2006;12:1533–1539
  157. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J. Clin. Pathol. 2007;60:1017–1023
  158. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005;11:5678–5685
  159. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J. Clin. Oncol. 2009;27(Suppl. 15S):abstr 551
  160. Samaga R, Saez-Rodriguez J, Alexopoulos LG, Sorger PK, Klamt S. The logic of EGFR/ErbB signaling: theoretical properties and analysis of high-throughput data. PLoS Comput. Biol. 2009;5:e1000438
  161. Schmierer B, Tournier AL, Bates PA, Hill CS. Mathematical modeling identifies Smad nucleocytoplasmic shuttling as a dynamic signal-interpreting system. Proc. Natl. Acad. Sci. U. S. A. 2008;105:6608–6613
  162. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 2008;14:8010–8018
  163. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 2002;20:370–375
  164. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2009;2:ra31
  165. Schulz M, Bakker BM, Klipp E. TIde: a software for the systematic scanning of drug targets in kinetic network models. BMC Bioinformatics. 2009;10:344
  166. Scully R. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res. 2000;2:324–330
  167. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics. 2009;25:2906–2912
  168. Shiu KK, Tan DS, Reis-Filho JS. Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opin. Ther. Targets. 2008;12:1123–1137
  169. Sims AH, Howell A, Howell SJ, Clarke RB. Origins of breast cancer subtypes and therapeutic implications. Nat. Clin. Pract. Oncol. 2007;4:516–525
  170. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 2008;19:1847–1852
  171. Sitter B, Bathen TF, Tessem MB, Gribbestad IS. High resolution magic angle spinning (HRMAS) MR spectroscopy in metabolic characterization of human cancer (review). Prog. Nucl. Magn. Reson. Spectrosc. 2009;54:239–254
  172. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–3114
  173. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003;100:8418–8423
  174. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11:R18
  175. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462:1005–1010
  176. Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R. Triple-negative breast cancer. Curr. Opin. Oncol. 2008;20:614–620
  177. Swameye I, Muller TG, Timmer J, Sandra O, Klingmuller U. Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc. Natl. Acad. Sci. U. S. A. 2003;100:1028–1033
  178. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br. J. Cancer. 2009;100:1517–1522
  179. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 2008;111:27–44
  180. Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J. 2008;14:343–351
  181. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2007;25:5210–5217
  182. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J. Clin. Oncol. 2005;23:8794–8801
  183. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071–1082
  184. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, et al. System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat. Genet. 2005;37:187–192
  185. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology. 2009;250:638–647
  186. Van Holsbeke C, Van Calster B, Valentin L, Testa AC, Ferrazzi E, Dimou I, et al. External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group. Clin. Cancer Res. 2007;13:4440–4447
  187. Vapnik VN. The Nature of Statistical Learning Theory. New York, USA: Springer; 2002;
  188. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  189. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–182
  190. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998;351:316–321
  191. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 2009;116:317–328
  192. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347:1999–2009
  193. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, Gudjonsson T, Rank F, LaBarge MA, et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 2007;177:87–101
  194. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24
  195. von Minckwitz, G., Kaufmann, M., Kűmmel, S., 2008. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. In: San Antonio Breast Cancer Symposium, San Antonio, TX abstr 79.
  196. Vousden KH, Ryan KM. p53 and metabolism. Nat. Rev. Cancer. 2009;9:691–700
  197. Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008;246:367–375
  198. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008;216:141–150
  199. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 2009;117:273–280
  200. Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. Clin. Chim. Acta. 2009;400:63–69
  201. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792
  202. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res. Treat. 2008;111:405–410
  203. Zi Z, Klipp E. Constraint-based modeling and kinetic analysis of the Smad dependent TGF-beta signaling pathway. PLoS ONE. 2007;2:e936
  204. Zwolak J, Adjerid N, Bagci EZ, Tyson JJ, Sible JC. A quantitative model of the effect of unreplicated DNA on cell cycle progression in frog egg extracts. J. Theor. Biol. 2009;260:110–120

PII: S1574-7891(10)00028-1

doi: 10.1016/j.molonc.2010.04.006

Molecular Oncology
Volume 4, Issue 3 , Pages 209-229 , June 2010

Article Tools

* Image Usage & Resolution